Inhibikase Therapeutics Strengthens Leadership Team with Appointment of Timothy Pigot as Chief Commercial and Strategy Officer

Core Insights - Inhibikase Therapeutics has appointed Timothy Pigot as Chief Commercial and Strategy Officer to enhance its strategic direction in the pulmonary arterial hypertension (PAH) market [1][2] - The company is advancing its lead product candidate, IKT-001, towards a late-stage clinical trial in PAH, which is a progressive and life-threatening disease affecting approximately 50,000 Americans [3] Company Overview - Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing therapeutics for cardiopulmonary diseases, specifically targeting PAH through aberrant signaling pathways [3] - The lead product candidate, IKT-001, is a prodrug of imatinib mesylate aimed at treating PAH, which is classified as an orphan indication [3] Leadership Background - Timothy Pigot brings over three decades of experience in the pharmaceutical industry, having held significant roles in both large pharmaceutical companies and startups [2] - Prior to joining Inhibikase, Pigot served as Chief Commercial Officer at Aerovate Therapeutics and held leadership positions at MyoKardia, Gilead Sciences, and Pfizer, focusing on marketing and commercial strategies in the PAH and other therapeutic areas [2]